Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

New Trials

28 Apr 2008 08:09

Plant Health Care PLC28 April 2008 For immediate release 28 APRIL 2008 PLANT HEATH CARE PLC ("Plant Heath Care" or "the Company") Plant Health Care, Inc. initiates large scale grower tests for a ProActTM + Glyphosate product Plant Heath Care, (AIM: PHC.L), a leading provider of natural products forplants and soil, has initiated a large scale field trial program for corn,soybeans, and cotton to further evaluate the already established benefits ofusing ProActTM in combination with glyphosate, the world's most commonly usedherbicide, when applied over-the-top of glyphosate resistant crops. Five yearsof independent testing have demonstrated significant yield increases in cottonand corn when treated with a combination of ProAct and glyphosate. ProAct is afoliar spray product for reducing nematode populations and improving overallplant health. ProAct, which is the only foliar spray product labeled for useagainst nematodes in corn and soybeans, contains Harpin, a second generationharpin protein formulated as a wettable dry granule. PHC Director of Field Biology Ned French says, "ProAct increases yields. Thecomprehensive data from multi-year ProAct research shows average increases of2.5 bushels/acre in soybeans, 7 bushels/acre in corn, and 68 pounds of cottonlint/acre. These yield increases translate into economic returns of $28, $35,and $50/acre, respectively. The ProAct + Glyphosate Program will help bothgroups learn more about the benefits in real-world farming conditions." All participants will be asked to join a series of post-harvest teleconferencesto discuss how the ProAct + glyphosate tank-mix performed on their farms. PHCwill use the information gleaned from the teleconferences as the basis forbetter understanding farmer needs and perceptions as they relate to the use ofProAct + glyphosate. PHC, started in 1995, was originally focused on horticulture, turf, vegetablesand high value crops. The company started targeting field crops -corn, soybeans,and cotton - in 2007 based on its acquisition of harpin protein technologyproducts such as ProAct. ProAct contains the most recently developed andeffective generation of harpin proteins. Plant Health Care, Inc., headquartered in Pittsburgh, PA, is a wholly ownedsubsidiary of Plant Health Care plc (AIM:PHC), a leading provider of naturalproducts for plants and soil. PHC has operations in the United States, Mexico,the United Kingdom, Spain, and the Netherlands. PHC products are used in theagriculture, landscape, horticulture and land reclamation industries and areenvironmentally beneficial. Through the commercialization of these products, PHCis capitalizing on current long-term trends toward natural systems andbiological products for plant care and soil and water management. For moreinformation and complete details pertaining to the ProAct SatisfactionGuarantee, go to www.planthealthcare.com. -ends- For further information: Plant Heath Care plc John Brady, Chief Executive Tel: 001 603 525 3702 Evolution Securities Limited Tim Worlledge/ Tim Redfern Tel: 020 7071 4300 Tavistock Communications Jeremy Carey/Matt Ridsdale Tel: 020 7920 3150 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.